Get the Stockscreener App
113.29
0.92%
1.03
After Hours:
113.00
-0.29
-0.26%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $113.29, with a volume of 7.81M.
It is up +0.92% in the last 24 hours and down -6.96% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$112.26
Open:
$111.92
24h Volume:
7.81M
Relative Volume:
0.89
Market Cap:
$197.00B
Revenue:
$44.33B
Net Income/Loss:
$6.48B
P/E Ratio:
30.59
EPS:
3.7033
Net Cash Flow:
$6.92B
1W Performance:
-0.26%
1M Performance:
-6.96%
6M Performance:
-13.03%
1Y Performance:
-12.97%
1-Day Range:
$111.63
$113.38
1-Week Range:
$111.40
$113.76
52-Week Range:
$105.27
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott (NYSE:ABT) Diagnostics Strength Supports Russell 1000 ETF Narrative - Kalkine Media
How The Abbott Offer Is Rewriting The Story For Exact Sciences (EXAS) - Yahoo Finance
NEOS Investment Management LLC Acquires 72,502 Shares of Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Grows Holdings in Abbott Laboratories $ABT - MarketBeat
Skandinaviska Enskilda Banken AB publ Buys 190,255 Shares of Abbott Laboratories $ABT - MarketBeat
A Look At Abbott Laboratories (ABT) Valuation As Libre 3 Lawsuit Raises Product Safety Concerns - simplywall.st
Abbott class action claims glucose sensors sold with defect - Class Action Lawsuits
Southeast Asset Advisors LLC Acquires 9,600 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Vanguard Group Inc. - MarketBeat
Pallas Capital Advisors LLC Reduces Stock Position in Abbott Laboratories $ABT - MarketBeat
Shell Asset Management Co. Trims Stock Position in Abbott Laboratories $ABT - MarketBeat
Fifth Third Bancorp Sells 10,616 Shares of Abbott Laboratories $ABT - MarketBeat
State of New Jersey Common Pension Fund D Boosts Holdings in Abbott Laboratories $ABT - MarketBeat
PNC Financial Services Group Inc. Reduces Position in Abbott Laboratories $ABT - MarketBeat
Could The Market Be Wrong About Abbott Laboratories (NYSE:ABT) Given Its Attractive Financial Prospects? - Yahoo Finance
GF Fund Management CO. LTD. Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
HighTower Advisors LLC Sells 35,569 Shares of Abbott Laboratories $ABT - MarketBeat
Aberdeen Group plc Sells 49,223 Shares of Abbott Laboratories $ABT - MarketBeat
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Abbott Laboratories (ABT) - The Globe and Mail
What is Abbott Laboratories s 5 year growth outlookWeekly Gains Summary & Smart Swing Trading Alerts - mfd.ru
Key facts: Exact Sciences to merge with Abbott by Q2 2026; 2025 revenue up 18% - TradingView
Abbott Laboratories: A Key Reduction in Robert Bruce's Portfolio - GuruFocus
EXACT SCIENCES CORP SEC 10-K Report - TradingView
ABT.SW Abbott Laboratories (SIX) volume spike 40x avg: watch CHF100.00 support - Meyka
Abbott Laboratories $ABT Shares Purchased by Public Sector Pension Investment Board - MarketBeat
Krilogy Financial LLC Acquires Shares of 9,560 Abbott Laboratories $ABT - MarketBeat
Freemont Management S.A. Trims Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories: A Steady Dividend Growth King - Intellectia AI
Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next? - 24/7 Wall St.
DexCom earnings up next: Can G7 rollout offset Abbott competition? By Investing.com - Investing.com Nigeria
DexCom earnings up next: Can G7 rollout offset Abbott competition? - Investing.com
Abbott Labs: The healthcare dividend stock I'd happily hold forever - MSN
Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever - AOL.com
Illinois Municipal Retirement Fund Has $22.46 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Cibc World Market Inc. Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Caisse Des Depots ET Consignations Buys 9,374 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Atria Investments Inc - MarketBeat
‘Time to Buy,’ Says Options Trader Following Abbott’s (ABT) Earnings Implosion - TipRanks
Rhumbline Advisers Sells 57,100 Shares of Abbott Laboratories $ABT - MarketBeat
Seaview Investment Managers LLC Reduces Position in Abbott Laboratories $ABT - MarketBeat
Jensen Investment Management Inc. Has $322.72 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Drug of Abuse Testing Market Is Going to Boom |• Abbott - openPR.com
Impax Asset Management Group plc Sells 13,701 Shares of Abbott Laboratories $ABT - MarketBeat
Caprock Group LLC Takes Position in Abbott Laboratories $ABT - MarketBeat
ING Groep NV Has $63.40 Million Holdings in Abbott Laboratories $ABT - MarketBeat
US Says Abbott Lied, Must Repay Funds Spent On Formula - Law360
Exact Sciences Faces Shareholder Lawsuits Over Abbott Merger - TipRanks
Abbott stock rises on AFib device data buzz as traders weigh FDA overhang - Bez Kabli
Abbott Laboratories price tries to correct main downward trendForecast today10-02-2026 - Economies.com
After a 15% Drop, Is Abbott Stock Set Up for a Comeback in 2026? - TIKR.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):